<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00862394</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-0705-PR-0027</org_study_id>
    <nct_id>NCT00862394</nct_id>
  </id_info>
  <brief_title>A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma</brief_title>
  <official_title>A 12-week, Multinational, Randomised, Double Blind, Double Dummy, 4-arm Parallel-group Study Comparing the Efficacy and Safety of CHF 1535 (Fixed Combination of Beclomethasone Dipropionate + Formoterol Fumarate) 100 + 6 μg/Actuation Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (Fixed Combination of Beclomethasone Dipropionate + Formoterol Fumarate) 100 + 6 μg/Actuation, Via HFA Pressurised Inhalation Solution, in Moderate to Severe Symptomatic Asthmatic Patients Aged ≥ 12 Years Under Treatment With Inhaled Corticosteroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate that CHF 1535 via NEXT DPI (beclomethasone dipropionate + formoterol fumarate
      100 + 6 μg), 1 inhalation or 2 inhalations twice daily, for 12 weeks is non-inferior to the
      corresponding dose of CHF 1535 via HFA-134a &quot;extrafine&quot; pMDI in terms of pulmonary function
      in moderate to severe symptomatic asthmatic patients aged ≥ 12 years under treatment with
      inhaled corticosteroids
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline measured at clinic to the end of treatment period in pre-dose morning FEV1 (L) measured at clinic</measure>
    <time_frame>3 month period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pre-dose FEV1</measure>
    <time_frame>every month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-dose FEV1 AUC 0-8 h</measure>
    <time_frame>3 month period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC and FEF 25-75%</measure>
    <time_frame>every month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEF</measure>
    <time_frame>every day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning and evening asthma clinical symptoms scores</measure>
    <time_frame>every day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moderate and severe exacerbations</measure>
    <time_frame>every month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue medication</measure>
    <time_frame>every day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum</measure>
    <time_frame>3 month period</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">783</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHF 1535 Next DPI : BDP/Formoterol : 200/12 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CHF 1535 HFA pMDI : BDP/Formoterol : 200/12 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHF 1535 Next DPI : BDP/Formoterol : 400/24 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CHF 1535 HFA pMDI : BDP/Formoterol : 400/24 µg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BDP/Formoterol Next DPI</intervention_name>
    <description>BDP/Formoterol Next DPI 100/6 µg (daily dose : 200/12 µg)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Foster</intervention_name>
    <description>BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 200/12 µg)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BDP/Formoterol Next DPI</intervention_name>
    <description>BDP/Formoterol 100/6 µg (daily dose : 400/24 µg)</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Foster</intervention_name>
    <description>BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 400/24 µg)</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Outpatients of both sexes, aged &gt; 12 years

          -  Moderate to severe symptomatic asthma

          -  Forced expiratory volume in the first second (FEV1) &gt; 40% and &lt; 80% of the predicted
             normal values

          -  Reversibility test

          -  &quot;Partly controlled&quot; asthma (GINA revised 2006)

          -  Patients free of long-acting beta2-agonists (LABAs) treatment

          -  Under inhaled corticosteroids (ICS) treatment

          -  A minimum inspiratory flow ≥ 40 L/min 10.

          -  Non-smokers or ex smokers

          -  Asthma Control Questionnaire ACQ score ≥ 1.5

        Exclusion Criteria:

          -  Pregnant or nursing (lactating) women

          -  Women of child-bearing potential, UNLESS they are menopausal or have acceptable
             methods of contraception

          -  Significant seasonal variation in asthma or asthma occurring only during episodic
             exposure to an allergen or a chemical sensitizer

          -  History of near fatal asthma

          -  Occurrence of asthma exacerbations or respiratory tract infections in the 6 weeks
             preceding the screening visit

          -  Diagnosis COPD

          -  History of cystic fibrosis, bronchiectasis or alpha-1 antitrypsin deficiency

          -  Diagnosis of restrictive lung disease

          -  Patients treated with oral or parenteral corticosteroids in the previous 2 months (3
             months for parenteral depot corticosteroids)

          -  Intolerance or contra-indication to treatment with beta2-agonists and/or inhaled
             corticosteroids

          -  Allergy to any component of the study treatments

          -  Any change in the dose, schedule, formulation or product of an inhaled corticosteroid
             in the 4 weeks prior to screening visit

          -  Significant medical history of and/or treatments for cardiac, renal, neurological,
             hepatic, endocrine diseases, or any laboratory abnormality ;

          -  Patients with abnormal QTc
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Oliver Kornmann - National Coordinator in Germany</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/search?query=CCD-0705-PR-0027</url>
    <description>Study Record on EU Clinical Trials Register including results</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2009</study_first_submitted>
  <study_first_submitted_qc>March 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2009</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

